- | NantKwest
The Inside Story Of Biotech’s Barnum And His Covid Cures
Patrick Soon-Shiong knows when he realized that the Covid-19 pandemic was going to pose a serious threat. It was February 24, and the part-owner of the L.A. Lakers was at the Staples Center in Los Angeles for Kobe Bryant’s memorial service.
- | Orchestra BioMed
Driving Biomedical Innovation and Partnerships in Interventional Cardiology with David Hochman Orchestra BioMed
David Hochman, CEO and Founder, Orchestra BioMed is bringing a partnership model to promote healthcare innovation particularly in the field of drug eluting balloons. Their lead product Virtue Sirolimus Angiofusion Balloon (SAB) is delivering an established therapeutic agent in interventional cardiology during balloon angioplasty without needing a stent permanent implant. This unique drug delivery solution encapsulates the drug in a balloon that has no coating and delivers the drug through micropores in the balloon to deliver the intended dose.
- | Acepodia
Immunotherapy Developer Acepodia Hopes to Slash Cell Therapy Manufacturing Costs
“Empowering” natural killer (NK) cells to destroy tumors could cut the cost of cell therapies, according to a company developing the technology. Acepodia has started Phase I trials of its lead drug candidate, a cancer treatment based on a new cell therapy platform. Antibody Cell Conjugation (ACC) uses “molecular Velcro” to attach tumor-fighting antibodies to the surface of proprietary NK cells.
- | Cue Biopharma
Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in areas such as oncology and autoimmunity.
- | Sotio
SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice – in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113)
- | CalciMedica
FDA greenlights expansion of COVID-19 study to VCU Medical Center after positive data
When it comes to fighting COVID-19, doctors say your body’s immune response can often time be worse than the symptoms of the disease itself. “Unfortunately, this COVID-19 generates a hyper-immune response. The immune response is actually maladaptive to and that actually causes its own dama
- | Cue Biopharma
Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity.
- | Immunomedics
Promise of ADCs in solid tumours: Immunomedics partners with Roche
Roche and Immunomedics have expanded their checkpoint inhibitor-ADC partnership from TNBC to include other solid tumours: UC and NSCLC. What promise does combining ADC Trodelvy and checkpoint inhibitor Tecentriq have in overcoming unmet needs in these cancer types?
